Composite Proteins™: Effective Deimmunized Proteins

Design safer, more effective, deimmunized therapeutic proteins.

Therapeutic proteins have the potential to elicit immunogenicity in patients. Clinical studies have shown that both human and non-human proteins can induce a variety of responses ranging from neutralizing antibodies to severe allergic reactions and even autoimmunity. Technologies such as PEGylation, have proved effective in some cases at stimulating potent immune responses in a significant number of patients.

Abzena’s Composite Proteins™ technology significantly improves on previous deimmunization technologies. This is achieved through the incorporation of our EpiScreen™ 2.0 technology that more accurately identifies and prioritizes the removal of T cell epitopes.

Contact us

Our Composite Proteins™ technology generates therapeutic proteins designed to minimize immunogenicity in patients without compromising protein activity.

Advanced protein deimmunization

Through the use of EpiScreen™ 2.0 technology, T cell epitopes (the primary drivers of long-lived, memory-based immunogenicity) are identified and ranked by magnitude and promiscuity in a world population. The T cell epitopes are then removed from the protein using proprietary in silico tools to design new variants. Simultaneously, structure and homology analysis guide the targeting and substitution of key amino acids to retain the desired protein activity. Deimmunization of the resulting Composite Protein™ is confirmed by the EpiScreen™ 2.0 time course T cell assay.

Benefits of our Composite Protein™ technology

Our Composite Proteins™ deimmunization technology builds on the success of antibody humanization to design safer therapeutic proteins. At a glance, its benefits are as follows.

  • Confirmation of T cell epitope avoidance by Abzena’s EpiScreen™ 2.0 technology
  • Excellent retention of functionality and specificity compared to the starting protein
  • Proprietary technology avoids other deimmunization patents